Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;89(5):1532-1540.
doi: 10.1111/bcp.15610. Epub 2022 Dec 12.

Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant

Camille de Truchis  1 , Naïm Bouazza  2   3   4 , Frantz Foissac  2   3   4 , Marina Charbit  1 , Laurène Dehoux  1 , Gabrielle Lui  2   4   5 , Mégane Ribot  3   5 , Nelly Briand  3 , Yi Zheng  2   5 , Jean-Marc Tréluyer  2   3   4   5 , Olivia Boyer  1   6
Affiliations
Free article

Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant

Camille de Truchis et al. Br J Clin Pharmacol. 2023 May.
Free article

Abstract

Aims: Glucocorticoids are 1 of the primary treatments in paediatric kidney transplantation. The aims of this study were: (i) to build a population pharmacokinetics (PPK) model of free prednisolone, which is the active form of prednisone, in paediatric kidney transplant recipients; (ii) to identify covariates accounting for interindividual variability (IIV) of pharmacokinetics (PK) parameters; and (iii) to investigate drug exposure-safety relationships.

Methods: Ninety-seven samples were obtained from 39 paediatric kidney transplant recipients (aged 3.4-17.2 years) in order to investigate prednisone PPK. We selected children receiving oral prednisone as part of their immunosuppressive regimen. A PPK analysis was performed using Monolix.

Results: A 1-compartment model best described prednisolone concentrations. Large IIV was observed as prednisolone was undetectable at H12 in some patients but could still be detected at H24 in others. Both bodyweight and ciclosporin cotreatment influenced the PK. The clearance (CLU ) and volume of distribution of free prednisolone allometrically scaled to 70 kg were 27.6 L/h and 101 L. Ciclosporin cotreatment decreased CLU by 67%. High blood pressure and new onset diabetes after transplantation were associated with daily free prednisolone exposure.

Conclusion: This study is the first analysis of prednisolone PPK in kidney-transplanted children. Some of the IIV in the PK parameters was explained by bodyweight and ciclosporin cotreatment. These data suggest that dose adjustment is required after identifying variability factors to optimize efficacy and limit side effects. The use of therapeutic drug monitoring in kidney-transplanted children may be useful, especially with respect to safety issues.

Keywords: PKPD; paediatric; population pharmacokinetics; prednisolone; renal transplant.

PubMed Disclaimer

References

REFERENCES

    1. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711-1723. doi:10.1056/NEJMra050541
    1. Tönshoff B, Tedesco-Silva H, Ettenger R, et al. Three-year outcomes from the CRADLE study in de novo pediatric kidney transplant recipients receiving everolimus with reduced tacrolimus and early steroid withdrawal. Am J Transplant. 2021;21(1):123-137. doi:10.1111/ajt.16005
    1. Schijvens AM, Ter Heine R, de Wildt SN, Schreuder MF. Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome. Pediatr Nephrol. 2019;34(3):389-403. doi:10.1007/s00467-018-3929-z
    1. Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition: Kenneth D. Blackfan Memorial Lecture. Pediatrics. 1961;28(2):169-181. doi:10.1542/peds.28.2.169
    1. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental Pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-1167. doi:10.1056/NEJMra035092